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Background: Besides being a causative agent for genital warts and cervical cancer, human papillomavirus (HPV)
contributes to 40-85% of cases of anal, penile, vaginal and vulvar cancer and precancerous lesions. HPV types 16 &
18 in particular contribute to 74-93% of these cases. Overall the number of new cases of these four cancers may be
relatively high implying notable health care cost to society. The aim of this study was to estimate the incidence
and the health care sector costs of anal, penile, vaginal and vulvar cancer.
Methods: New anogenital cancer patients were identified from the Danish National Cancer Register using ICD-10
diagnosis codes. Resource use in the health care sector was estimated for the year prior to diagnosis, and for the
first, second and third years after diagnosis. Hospital resource use was defined in terms of registered hospital
contacts, using DRG (Diagnosis Related Groups) and DAGS (Danish Outpatient Groups System) charges as cost
estimates for inpatient and outpatient contacts, respectively. Health care consumption by cancer patients
diagnosed in 2004–2007 was compared with that by an age- and sex-matched cohort without cancer. Hospital
costs attributable to four anogenital cancers were estimated using regression analysis.
Results: The annual incidence of anal cancer in Denmark is 1.9 per 100,000 persons. The corresponding incidence
rates for penile, vaginal and vulvar cancer are 1.7, 0.9 and 3.6 per 100,000 males/females, respectively. The total
number of new cases of these four cancers in Denmark is about 270 per year. In comparison, the total number of
new cases cervical cancer is around 390 per year. The total cost of anogenital cancer to the hospital sector was
estimated to be 7.6 million Euros per year. Costs associated with anal and vulvar cancer constituted the majority of
the costs.
Conclusions: Anogenital cancer incurs considerable costs to the Danish hospital sector. It is expected that the
current HPV vaccination program will markedly reduce this burden.
Keywords: Anogenital, Cancer, Cost, Incidence, HPVBackground
The introduction of two vaccines against human papillo-
mavirus (HPV) types 16 & 18 and types 6, 11, 16 & 18,
respectively, was primarily intended to protect against
cervical cancer (and precancerous lesions) and genital
warts. However, HPV also contributes to 40-85% of all
cases of anal, penile, vaginal and vulvar cancer and pre-
cancerous lesions. HPV types 16 & 18 in particular con-
tribute to 74-93% of these cases [1-6] and clinical
studies of the quadrivalent HPV vaccine has proven* Correspondence: jeo@cast.sdu.dk
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reproduction in any medium, provided the orprotection against infection, persistent infection and low
and high grade lesions in male and female populations,
respectively [7-9].
Cervical cancer is the second most common cancer
among women worldwide and is the fifth most frequent
cancer among Danish women [10-12]. Less information
is available on other HPV-related cancers but the total
number of new cases of anal, penile, vaginal and vulvar
cancer may be relatively high, implying considerable
health care costs to society [11]. Although the incidence
of cervical cancer has remained stable over the last dec-
ade [11,13], the incidence of anal and vulvar cancer has
increased [11].
The aim of this study was to estimate the incidence and
the health care sector cost of anal, penile, vaginal andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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will contribute to a forthcoming cost-effectiveness ana-
lysis of HPV vaccination that, besides cervical cancer and
genital warts, will include the vaccine’s protection against
anal, penile, vaginal and vulvar cancer.
Methods
Patient data were extracted from Danish national regis-
ters, which are linked through individuals’ unique regis-
tration number (CPR-number). The Danish health
service has a long tradition of recording health service
use and each contact with primary health care (e.g. gen-
eral practitioner, public and private specialist, dentist,
physiotherapist) and secondary health care (e.g. hospital
admission, outpatient visits) is recorded with related
data on age, sex, type of contact, speciality, fee/charge,
diagnoses (secondary health care only) and procedure
code. The present study was approved by the Danish
Data Protection Agency (J. No. 2010-41-4305).
The analysis was conducted from a hospital sector per-
spective, as the relevant cancer types are almost exclu-
sively diagnosed and treated at hospitals. New cancer
patients were identified via specific ICD-10 diagnosis
codes in the Danish National Cancer Register. Their an-
nual hospital resource use was estimated based on hos-
pital contacts recorded in the National Patient Register,
which defines resource use by the DRG (Diagnosis
Related Groups) system for admissions and by the Da-
nish outpatient charges (DAGS charges) for outpatient
visits (including emergency unit contacts) [14]. The 2008
DRG and DAGS charges were used as cost estimates.
The cohort of cancer patients was defined as patients
registered in the Danish National Cancer Register during
2004–2007 with anal, penile, vaginal or vulvar cancer as
the primary localization. The patients were identified
using the ICD-10 codes: C21 (anal cancer), C60 (penile
cancer), C52 (vaginal cancer) and C51 (vulvar cancer).
For the cohort of cancer patients diagnosed during
2004–2007, health care use in 2006–2008 was com-
pared with an age- and sex-matched cohort without
cancer (controls). Five controls were identified for each
cancer patient. The hospital costs associated with the
controls were subtracted from the costs associated with
the cancer patients (to identify the extra costs related to
cancer), but this was done in regression analyses in
which costs attributable to anal, penile, vaginal and vul-
var cancer were estimated with cancer (yes/no) as an
explanatory dummy variable. As a substantial number
of the control patients incurred no health care costs
(i.e. cost = 0), a two-part model was applied [15-17]. In
this analysis, the probability that the patient had zero
or non-zero costs was first predicted via logistic re-
gression analysis. Secondly, the level of cost condi-
tional on having positive costs was predicted using ageneralized linear regression model (GLM), applying a
log link function and assuming an inverse Gaussian
distribution. Finally, the estimated health care costs
were derived by multiplying the predictions from the
two components (part 1 and 2) together.
When the data for this study was obtained, data on
cancer incidence (the Danish National Cancer Register)
was only available up until 2007, while data on DRG
and DAGS charges in the National Patient Register
were only available from 2006 (given that the same,
and relatively novel, version of the DRG- and DAGS-
charges should be applied for all years). Therefore, we
used a combined cross-sectional and longitudinal ap-
proach for the data analysis, where patients diagnosed
during 2004–2007 had an associated resource use for
2006–2008. This allowed us to estimate the costs 0–
12 months before the date of diagnosis (e.g. 2006 re-
source use data for a patient diagnosed in 2007) and
the costs 0–12 months, 13–24 months (e.g. 2008 re-
source use data for a patient diagnosed in 2006) and
25–36 months after the date of diagnosis (e.g. 2008 re-
source use data for a patient diagnosed in 2005).
Results are thus presented as yearly cost estimates for
the year before, the 1st year, the 2nd year and the 3rd
year after the date of diagnosis for patients alive at the
respective times. We included costs for the year before
diagnosis so that we could estimate the costs of initial
examinations and diagnostics. Given the perspective of
this analysis, the hospital cost estimates include medi-
cation related to hospital contacts, radiotherapy,
chemotherapy and specialized rehabilitation.
Costs are presented in Euros. Future costs (i.e. cost
estimates for the 2nd and 3rd years after diagnosis) were
discounted using a 3% annual discount rate to represent
their present value. When estimating the total average
health care cost per patient, we adjusted for deaths dur-
ing the observation period.
The number of diagnosed precancerous lesions was
estimated based on data from the National Pathology
Register. It was not possible to estimate treatment costs
for these lesions (some of which progress to anogenital
cancer) separately, however, as many of these cases are
diagnosed and treated by privately practising specialists
in the primary care sector. As diagnoses are not system-
atically registered for the primary care sector, it was im-
possible to distinguish contacts related to precancerous
lesions from other contacts.
Data were analysed using SAS software version 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
The incidence of the four anogenital cancers is shown in
Table 1. In females, the incidence is highest for vulvar
cancer and then anal cancer, and in males the incidence
Table 1 Incidence of anal, penile, vaginal and vulvar cancer and precancerous lesions
Gender Year No. of
cases
Mean age
(years)
Medi-an age
(years)
Min. age
(years)
Max. age
(years)
Anal cancer (ICD10 code: C21) Male 2004 27 61 59 33 89
Female 2004 64 68 68 34 97
Male 2005 25 62 64 35 85
Female 2005 63 62 61 33 92
Male 2006 48 59 59 18 93
Female 2006 74 63 59 40 97
Male 2007 42 64 62 37 91
Female 2007 75 59 57 33 93
Average no. cases
2004-2007
105 62
Incidence per
100,000 persons
1.9
Incidence per
100,000 males
1.3
Incidence per
100,000 females
2.6
% of patients
under 65 years
60.5%
Anal precancerous lesions, average no. of cases/year 242 52 - - -
Penile cancer (ICD10 code: C60) Male 2004 39 67 66 40 93
2005 47 68 66 38 88
2006 46 67 66 25 94
2007 55 68 69 40 93
Average no. cases
2004-2007
47 67
Incidence per
100,000 males
1.7
% of patients under 65 years 44.9%
Penile precancerous lesions, average no. of cases/year 86 60 - - -
Vaginal cancer (ICD10 code: C52) Female 2004 26 74 76 46 99
2005 15 74 75 53 92
2006 25 76 78 49 94
2007 26 67 73 37 95
Average no. cases
2004-2007
23 73
Incidence per
100,000 females
0.9
% of patients
under 65 years
29.7%
Vaginal precancerous lesions, average no. of cases/year 85 55 - - -
Vulvar cancer (ICD10 code: C51) Female 2004 99 70 74 30 96
2005 93 69 70 30 96
2006 104 68 70 23 96
2007 93 70 71 27 103
Average no. cases
2004-2007
97 69
Incidence per
100,000 females
3.6
% of patients
under 65 years
37.5%
Vulvar precancerous lesions, average no. of cases/year 522 50 - - -
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both sexes, it appears that incidence in patients under
65 years is highest for anal cancer. Figure 1 shows an in-
creasing incidence of anal and penile cancer until age
50–59 years and 60–69 years, respectively, followed by a
decrease. The incidence of vaginal and vulvar cancer
increases with increasing age.
Patients were followed until the end of 2008. After
24 months 74%, 75%, 47% and 71% of patients with anal,
penile, vaginal and vulvar cancer, respectively, were alive.
These results cannot be interpreted as 2-year survival
rates, however, as patients may have died from other
causes.
As could be expected, costs associated with the four
cancers were highest in the first 12 months after diagno-
sis (Table 2). Among the many diagnostic, surgical and
other treatment procedures that were registered, the
most frequent were radiotherapy, gynaecological exam-
ination, X-ray examination of thorax and proctoscopy.
The estimates for the total average cost per patient,
which were derived from the data in Table 2, are shown
in Table 3. The total average cost per patient is thus the
sum of the cost estimates for the year before and the 1st,
2nd and 3rd years after diagnosis with adjustment for
death during the observation period and with future0
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Figure 1 Annual incidence of anal, penile, vaginal and vulvar cancer acosts (2nd and 3rd years) discounted. Anal cancer, espe-
cially in men, incurs the highest total cost per patient. In
total, the cost to the hospital sector of anogenital cancer
constitutes 7.6 million Euros per year – comprising 2.4
million Euros per year for anogenital cancer in men and
5.2 million Euros per year for anogenital cancer in
women. The costs associated with anal and vulvar can-
cer constitute the majority of the costs (53% and 27%,
respectively).
Using the prevalence results presented in Table 4, we
estimated costs attributable to HPV 16 and 18. The total
hospital costs associated with HPV 16/18-related ano-
genital cancers were estimated at 4.6 million Euros per
year, of which 1. 5 million Euros and 3.1 million Euros
occurred in men and women, respectively (Table 3).
Discussion
This study estimated the incidence and the hospital sec-
tor cost of anal, penile, vaginal and vulvar cancer in
Denmark, using register data at individual patient level.
Danish registers are comprehensive and have good
recording practices, with the result that every incident
anogenital cancer patient in the period 2004–2007 can
be expected to be included in this analysis. The total
number of new cases of these four cancers in Denmark50-59 60-69 70-79 80-
 groups
r Vaginal cancer
s lesions, anal cancer Precancerous lesions, penile cancer
s lesions, vulva cancer
nd precancerous lesions.
Table 2 Mean annual hospital cost (2008 prices) per patient of anal, penile, vaginal and vulvar cancer
Year before diagnosis*, € 1st year**, € 2nd year**, € 3rd year**, €
(95% CI) (95% CI) (95% CI) (95% CI)
Anal cancer 4,285 23,557 7,926 5,753
(3,260-5,612) (18,298-30,323) (6,119-10,265) (4,266-7,750)
Anal cancer, men 4,524 25,335 8,567 6,498
(2,953-6,931) (16,248-39,420) (5,715-12,818) (3,921-10,736)
Anal cancer, women 4,143 22,620 7,608 5,440
(2,991-5,735) (16,475-31,038) (5,585-10,364) (3,901-7,586)
Penile cancer 2,238 12,497 3,968 3,634
(1,758-2,644) (9,146-17,075) (3,034-5,149) (2,458-5,290)
Vaginal cancer 3,789 17,154 7,215 ***
(2,394-5,986) (9,794-29,925) (4,189-12,425)
Vulvar cancer 2,824 12,353 4,044 4,269
(2,271-3,477) (9,382-16,260) (3,132-5,211) (3,034-5,995)
* The average cost 0–12 months before the date of diagnosis.
** The average cost 0–12 months after the date of diagnosis, 13–24 months after the date of diagnosis for living patients, and 25–36 months after the date of
diagnosis for living patients.
*** Results not estimated due to few observations.
€ 1.00 = DKK 7.45.
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of new cases cervical cancer is around 390 per year [11].
The total cost of anogenital cancer to the hospital sector
was estimated to be 7.6 million Euros per year (2.4 mil-
lion Euros per year for men and 5.2 million Euros per
year for women). Costs associated with anal and vulvar
cancer comprised 53% and 27% of the total cost, respect-
ively. In comparison, the total hospital cost of cervical
cancer (excluding precancerous lesions) is estimated to
be 10.2 million Euros per year (2008 price level, esti-
mated on the basis of Olsen and Jepsen, 2010 [18]). The
total health care sector costs of genital warts is estimated
to be 8.0 million Euros per year (2008 price level) [18].
A limited number of international publications on the
cost-of-illness of anogenital cancers are available. The
present cost estimates are markedly higher than those by
Borget et al. (2011) [19] and Abramowitz et al. (2010)
[20] but similar to US cost estimates from Hu and
Goldie (2008) [21]. Discrepancies may be due toTable 3 Total hospital costs (2008 prices) in Denmark for ana
Total cost per
patient €
Total cost per patient excluding c
year before diagnosis €
Anal cancer 38,289 34,004
Anal cancer, men 41,347 36,822
Anal cancer,
women
36,734 32,590
Penile cancer 20,513 18,275
Vaginal cancer 25,435 21,646
Vulvar cancer 21,161 18,337
Total costs,
anogenital cancer
- -
3% discount rate applied. € 1.00 = DKK 7.45.differences in cost levels between countries (especially
salaries for health professionals). Other important fac-
tors, however, are differences in methodology (prevalent
vs. incident patients), health service organization and
clinical practice, and in time horizon for the analyses
(longitudinal vs. cross-sectional approach). The strengths
of this study are the use of comprehensive national reg-
isters that include all incident patients in the years
2004–2007 and the estimation of costs for four separate
years. In comparison, for example, Borget et al. used a 1-
year cross-sectional approach [19].
Costs were estimated using DRG and DAGS charges
as unit costs for admissions and outpatient contacts, re-
spectively. These may not accurately reflect the oppor-
tunity cost, which should ideally be used in such
analyses. The charges used here were considered to be
the best available proxies for the opportunity costs.
Although use of the Danish National Cancer Register
and the National Patient Register is expected to havel, penile, vaginal and vulvar cancer
osts in the Total cost per year in
Denmark €
Total cost per year attributable
to HPV 16 & 18 €
4,001,230 3,147,043
1,467,811 1,154,461
2,534,623 1,993,529
958,972 329,610
585,011 358,625
2,057,936 753,254
7,603,149 4,588,532
Table 4 HPV prevalence in anogenital cancer
HPV prevalence
(% of cancers)
Prevalence (% of HPV-positive cancers)
HPV 16 HPV 18 HPV 16/18***
Anal cancer* 84.3 87.1 6.2 93.3
Penile cancer** 46.7 60.2 13.4 73.6
Vaginal cancer* 69.9 76.8 10.9 87.7
Vulvar cancer* 40.4 79.7 10.9 90.6
* Source: [6].
** Source: [5].
*** Co-infections are not taken into account.
Olsen et al. BMC Public Health 2012, 12:1082 Page 6 of 7
http://www.biomedcentral.com/1471-2458/12/1082identified all incident cases of anogenital cancer, the
results are likely to be an underestimation of the burden
of disease and costs related to anogenital cancers. Firstly,
the applied perspective ignores the productivity costs to
society that are associated with anogenital cancer, such
as indirect costs in terms of absence from work due to
cancer-related symptoms and treatment. Although many
patients had left the workforce at the time of diagnosis
(the retirement age in Denmark is typically 65 years),
some were likely to be still in the work force at the time
of diagnosis – particularly among anal cancer patients,
where 60% were aged under 65 years. This implies a
considerable productivity loss to society. Secondly, the
present study did not cost cases of precancerous lesions
not progressing to cancer (from Figure 1 it can be seen
that the number of cases of precancerous lesions exceeds
the number of cases of genital cancer). Many precancer-
ous lesions are diagnosed and treated by privately prac-
tising specialists in the primary care sector, and costs to
primary care were not included in this study. Finally, any
extra use of primary health care services by anogenital
cancer patients (above that used by the general popula-
tion) were not included in the analysis.
On the other hand, the costs attributable to HPV
16/18 is probably slightly overestimated as the preva-
lence of HPV 16 and 18 is simply added in the last
column in Table 4 thereby ignoring co-infections with
both these HPV types. However, co-infection with
HPV 16/18 seems infrequently encountered. It has
been found in 0 to 3.2% of HPV 16 positive cervical
samples [22,23].
Finally, it should be noted that certain types of oro-
pharyngeal cancers also are related to HPV 16 and 18
implying that the burden of HPV-related cancers, other
than cervical cancer, is higher than reported in this
study.
Conclusions
The total cost of anogenital cancer to the hospital sec-
tor was estimated to be 7.6 million Euros per year. It
is expected that the current Danish HPV vaccination
program will markedly reduce this burden. This study
provides the first estimate of the costs associated withnon-cervical HPV-related cancers in Denmark, based
on very reliable individual-level data. Future cost-
effectiveness studies of the Danish HPV vaccination
program should include the impact of the vaccine’s
protection against anogenital cancers.
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